UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 20, 2015
| Sucampo Pharmaceuticals, Inc. |
| (Exact Name of Registrant as Specified in Charter) |
| Delaware | 001-33609 | 30-0520478 |
(State or Other Juris- diction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
4520 East-West Highway, 3rd Floor Bethesda, Maryland | 20814 |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: (301) 961-3400
| (Former Name or Former Address, if Changed Since Last Report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01. Regulation FD Disclosure.
On March 2, 2015, Sucampo Pharmaceuticals, Inc. (“Company”) will make a corporate update presentation at the 2015 Cowen and Company Healthcare Conference. The slides from the presentation will also be used at one-on-one meetings with analysts and investors at the Conference. The slides are being furnished as Exhibit 99.1 to this Current Report on Form 8-K and include the revenue treatment of the $14 million upfront payment received in the 4th quarter as a result of the execution of the License, Development, Commercialization and Supply Agreement for Lubiprostone by and between Takeda Pharmaceuticals International GmbH and Sucampo AG dated October 17, 2014.
The information in this Item 7.01 and Exhibit 99.1 to this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits
| | 99.1 | The corporate update presentation slides dated March 2, 2015. |
| | 99.2 | Press Release issued by the Company on February 22, 2015. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | SUCAMPO PHARMACEUTICALS, INC. | |
| | | | |
| | | | |
| Date: February 22, 2015 | By: | /s/ Thomas J. Knapp | |
| | | Name: | Thomas J. Knapp | |
| | | Title: | EVP, Chief Legal Officer and Corporate Secretary | |
